Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The Food and Drug Administration today is alerting health care professionals and patients about early results of new studies for Paxil (paroxetine) suggesting that the drug increases the risk for birth defects, particularly heart defects, when women take it during the first three months of pregnancy.  Paxil is approved for the treatment of depression and several other psychiatric disorders.  FDA is currently gathering additional data and waiting for the final results of the recent studies in order to better understand the higher risk for birth defects that has been seen with Paxil. 

Read the rest of this entry »

The Food and Drug Administration said Thursday that the warning label on GlaxoSmithKline’s widely-prescribed anxiety drug Paxil has again been revised to advise the drug may cause heart defects in babies.

Read the rest of this entry »

Preliminary study data suggest that the antidepressant paroxetine should not be prescribed to pregnant women.

Read the rest of this entry »

The FDA and the drug company GlaxoSmithKline are alerting doctors about a new study on major birth defects seen in babies born to women who took the antidepressant Paxil during the first trimester of pregnancy.

Read the rest of this entry »